Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

26.36 -0.04

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.1

Massimo

26.75

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+48.93% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

914M

3B

Apertura precedente

26.4

Chiusura precedente

26.36

Notizie sul Sentiment di mercato

By Acuity

38%

62%

90 / 339 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 set 2026, 23:31 UTC

News
Social Media

Amazon.com Inc. is declining in after-market trading amid rising Treasury yields and geopolitical tensions, contributing to broader market downturns.

23 set 2026, 23:31 UTC

News

BWX Technologies Inc. received a BBB investment grade credit rating from Fitch Ratings, boosting after-market trading modestly higher.

23 set 2026, 23:31 UTC

Correlated Moves
News
Event

H.B. Fuller reported Q3 2026 net revenue of $938 million and adjusted EPS of $1.52, exceeding estimates, and traded higher in after-market hours.

23 set 2026, 23:26 UTC

Social Media
News

Robinhood Markets Inc. is trading slightly higher in after-market hours, bolstered by 13 revenue streams each generating over $100 million annually and positive growth forecasts.

23 set 2026, 23:25 UTC

News

Kraft Heinz Co is trading higher in after-market hours following RBC Capital Markets' "Outperform" rating and $32 price target, projecting 0.9% revenue growth by 2027.

23 set 2026, 23:21 UTC

News
Social Media

Meta Platforms Inc. is trading lower after-hours despite the launch of its Muse AI personal agent, which has garnered significant social media attention.

23 set 2026, 23:20 UTC

News

Goldman Sachs is selling Applied Systems, valued at up to $10 billion, as its stock moves higher in after-market trading amid active investment banking.

23 set 2026, 23:20 UTC

News

DoorDash Inc plans to pay $131.5 million to settle worker underpayment allegations, with its stock trading lower in after-market hours following the announcement.

23 set 2026, 23:16 UTC

News

Ethereum is trading lower, diverging from recent gains, amid rising U.S. crude oil inventories and strong economic data indicating robust private sector growth.

23 set 2026, 23:15 UTC

Social Media
News

Gossamer Bio Inc has submitted a New Drug Application for seralutinib targeting pulmonary arterial hypertension, with shares advancing in after-market trading.

23 set 2026, 23:15 UTC

News

Cooper Companies Inc's stock declines in after-market trading following a $30 million revenue miss in Q3, despite announcing a new global innovation hub in England.

23 set 2026, 23:15 UTC

News

AutoNation Inc announced a $1 million investment in cancer research grants, with its stock advancing modestly in after-market trading following the announcement.

23 set 2026, 23:11 UTC

Correlated Moves
News

The USD/SEK is advancing modestly as the U.S. dollar strengthens amid signals of potential Federal Reserve rate hikes to combat inflation.

23 set 2026, 23:06 UTC

News

UPS shares are slightly higher in after-market trading amid scrutiny over the diversion of sensitive F-35 parts to Hong Kong by the Chinese government.

23 set 2026, 23:06 UTC

Correlated Moves
News

Lockheed Martin's stock has gained in after-market hours following reports of the Chinese government seizing sensitive F-35 parts during shipment from Australia to the U.S.

23 set 2026, 23:06 UTC

Correlated Moves
News

Wells Fargo shares are modestly higher in after-market trading following the announcement of Chief Risk Officer Derek Flowers' upcoming retirement in mid-January.

23 set 2026, 23:06 UTC

Social Media
News

McDonald's is exploring menu growth opportunities for households using GLP-1 medications, with plans to reintroduce salads and grilled chicken items, gaining in after-market trading.

23 set 2026, 23:05 UTC

News

Lennar Corp. announced a quarterly dividend of $0.50 per share and reported increased stake from Berkshire Hathaway, with shares trading higher in after-market hours.

23 set 2026, 23:05 UTC

News

Altria Group Inc. is experiencing a decline in after-market trading amid potential regulatory changes for smoke-free nicotine products, raising concerns among public health advocates.

23 set 2026, 23:05 UTC

News

PepsiCo announced a significant order for 10k electric trucks through the ZET SCALE alliance, while its stock traded roughly flat in after-market hours.

23 set 2026, 23:05 UTC

News

Verizon grants $1 million to Liberty Science Center for AI initiative.

23 set 2026, 23:05 UTC

News

The USD/NOK is advancing modestly as U.S. crude oil inventories rose by 2.969 million barrels, raising supply concerns affecting the Norwegian krone.

23 set 2026, 23:05 UTC

News

General Mills Inc reports Q1 fiscal 2027 results with improved dollar sales and strong e-commerce growth, trading slightly higher in after-market hours.

23 set 2026, 23:01 UTC

News

Regenxbio Inc. has settled patent litigation with Sarepta Therapeutics, receiving $39 million, leading to a rise in after-market trading.

23 set 2026, 23:01 UTC

News

TransUnion shares are trading lower after CFO Todd Cello announced his planned departure at the end of 2026, despite reaffirmed financial guidance.

23 set 2026, 23:01 UTC

Correlated Moves
News

JPMorgan Chase & Co is involved in the sale of Applied Systems, valued at up to $10 billion, and is modestly higher in after-market trading.

23 set 2026, 23:01 UTC

News

AbbVie Inc. is down slightly in after-market trading, pulling back from an earlier session high, with a "Sell" rating and a price target of $191.

23 set 2026, 23:01 UTC

News
Social Media

MGM Resorts International's stock is sharply lower after Barry Diller withdrew his $18 billion acquisition bid, reaffirming the company's standalone commitment.

23 set 2026, 23:01 UTC

News

Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 and unveiled its LUNAR 2.0 platform, yet the stock is trading lower in after-market hours.

23 set 2026, 23:01 UTC

News

The USD/THB is advancing, reaching its highest cumulative return amid strong U.S. private sector growth, with the S&P Global Composite PMI rising to 58.4.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

48.93% in crescita

Previsioni per 12 mesi

Media 39.333 USD  48.93%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

90 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.